Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 4/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11316419 | 1.00 | LPAR3 (0.53) | LPAR3LPAR2PPARDALDH1A1LMNA | |
| SCHEMBL9701578 | 0.98 | PPARD (0.52) | LPAR3LPAR2PPARDALDH1A1LMNA | |
| SCHEMBL9700821 | 0.93 | PPARD (0.53) | LPAR3LPAR2PPARDALDH1A1LMNA | |
| SCHEMBL2954341 | 0.85 | LPAR3 (0.46) | LPAR3LPAR2PPARDALDH1A1LMNA | |
| SCHEMBL5701223 | 0.84 | LPAR3 (0.50) | LPAR3LPAR2ALDH1A1LMNATSHR | |
| SCHEMBL5701225 | 0.82 | LPAR3 (0.49) | LPAR3LPAR2ALDH1A1LMNATSHR | |
| SCHEMBL2955740 | 0.81 | LPAR3 (0.47) | LPAR3LPAR2PPARDALDH1A1LMNA | |
| SCHEMBL8993904 | 0.81 | LPAR3 (0.47) | LPAR3LPAR2PPARDALDH1A1LMNA | |
| SCHEMBL9701750 | 0.81 | LPAR3 (0.47) | LPAR3LPAR2PPARDALDH1A1LMNA | |
| SCHEMBL29365891 | 0.81 | LPAR3 (0.62) | LPAR3LPAR2CETPLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | INTEGRIGEN, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | INTEGRIGEN, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090155828-A1 | METHODS OF DETECTING PROSTATE CANCER | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-06-18 | — | — | US | disclosed |
| US-20060171947-A1 | Serine/threonine hydrolase proteins and screening assays | BURNHAM INSTITUTE | 2006-08-03 | — | — | US | disclosed |
| US-7083987-B2 | Activity based probe analysis | ACTIVX BIOSCIENCES, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050287594-A1 | Activity-based probes having specificity to the active form of enzymes and receptors; screening for desired biological activities or target proteins | SCRIPPS RESEARCH INSTITUTE, THE | 2005-12-29 | — | — | US | disclosed |
| US-6872574-B2 | Generating and screening compound libraries that are used for the identification of lead molecules, and for the parallel identification of their biological targets | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1364209-A4 | ACTIVITY BASED PROBE ANALYSIS | ACTIVX BIOSCIENCES INC (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1364209-A2 | ACTIVITY BASED PROBE ANALYSIS | Activx Biosciences, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030175986-A1 | Activity based probe analysis | ACTIVX BIOSCIENCES, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030096328-A1 | Serine/threonine hydrolase proteins and screening assays | BURNHAM INSTITUTE | 2003-05-22 | — | — | US | disclosed |
| EP-1275006-A2 | PROTEOMIC ANALYSIS USING ACTIVITY-BASED PROBE LIBRARIES | The Scripps Research Institute (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20020182652-A1 | Proteomic analysis | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-12-05 | — | — | US | disclosed |
| WO-2002063271-A2 | ACTIVITY BASED PROBE ANALYSIS | ACTIVX BIOSCIENCES, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020064799-A1 | Proteomic analysis | THE SCRIPPS RESEARCH INSTITUTE OF AN ASSIGNMENT | 2002-05-30 | — | — | US | disclosed |
| US-20020045194-A1 | Proteomic analysis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-04-18 | — | — | US | disclosed |
| US-20020040275-A1 | Proteomic analysis | THE SCRIPPS RESEARCH INSTITUTE | 2002-04-04 | — | — | US | disclosed |
| WO-2001077668-A2 | PROTEOMIC ANALYSIS USING ACTIVE-SITE DIRECTED PROBES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001077684-A2 | PROTEOMIC ANALYSIS USING ACTIVITY-BASED PROBE LIBRARIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | FCGRT, PTMS, DNPEP | LPAR3 1556/4885LPAR2 3253/4885PPARD 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.